The disclosure provides cyclic dinucleotides that are useful as STING agonists, pharmaceutical compositions and vaccines comprising the cyclic dinucleotides, and methods of treating diseases and disorders using the cyclic dinucleotides, pharmaceutical compositions, and vaccines.

A compound useful for treating leukemia or myelodysplastic syndrome, having the structure of formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is H or —C(═O)—O—R.sup.3, and R.sup.2 is H or —C(═O)—O—R.sup.4, provided R.sup.1 and R.sup.2 are not both H; and R.sup.3 and R.sup.4 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, and heteroalkyl. In an exemplary compound of formula (I), R.sup.1 is —C(═O)—O—CH.sub.2—CH.sub.3, and R.sup.2 is H.

Described herein are methods for treating or preventing chronic kidney disease, and other diseases, comprising the administration (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethy)benzofuran-3-yl-4,5,6,7-d.sub.4)methanone, and solvates thereof.

Described herein are methods for treating or preventing chronic kidney disease, and other diseases, comprising the administration (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethy)benzofuran-3-yl-4,5,6,7-d.sub.4)methanone, and solvates thereof.

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease. ##STR00001##

Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

The invention relates to a compound having the structure:

##STR00001## or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and therapeutic methods thereof.

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.